Mechanisms of programmed cell death

免疫原性细胞死亡 免疫系统 程序性细胞死亡 免疫学 坏死性下垂 癌症 免疫疗法 癌症免疫疗法 癌症研究 医学 肿瘤微环境 癌细胞 生物 细胞凋亡 内科学 生物化学
作者
Tian Li,Guido Kroemer
出处
期刊:Immunological Reviews [Wiley]
卷期号:321 (1): 5-6 被引量:2
标识
DOI:10.1111/imr.13303
摘要

The present volume of Immunological Reviews deals with the mechanisms of programmed cell death, obviously from an immunological perspective. What are the consequences of cell death on the organism and, in particular, on the immune recognition of stressed and dying cells? The long-distance effects of therapeutic manipulations resulting in the death of cancer cells are surprisingly vast, as this has been documented for the treatment with clinically approved or experimental chemotherapeutic agents. For example, cell death can cause neuropathic pain through mechanisms of neuroinflammation.1 In addition, cell death induction can result in the production of Type I interferons by tumor cells that then mediate ambiguous adaptive responses ranging from an enhancement of cancer cell stemness and exhaustion of anticancer immune response within the tumor microenvironment to the stimulation of anticancer immune responses. Type I interferon can even trigger a systemic sickness response ranging from flu-like symptoms to a state of depression.2 Such long-range effects of cell death are certainly also relevant to the pathophysiology of viral infections. If induced in an appropriate fashion, one of the major positive effects of cancer cell stress and death is the induction of immune responses against tumor-associated antigen, thus sensitizing tumors to immunotherapy with immune checkpoint inhibitors.3-5 This has important therapeutic implications because chemotherapeutics that induce immunogenic cell death can be used as first-line treatments to sensitize major cancer types (exemplified by KRAS-mutated colorectal cancer, non-small cell lung cancer and triple-negative breast cancer) to subsequent immunotherapy with antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), or PD-1 ligand-1 (PD-L1), as this has been confirmed in several clinical trials. Of note, there are multiple different subroutines of cell death, and several if not all of them can be immunogenic, as this has been documented for apoptosis (which involves mitochondrial membrane permeabilization and the activation of caspases 3 and 7)2, 3 but also for necroptosis (with the implication of specific effector molecules including receptor-interacting kinase 3 (RIP3) and mixed lineage kinase domain-like pseudokinase (MLKL1)),6 pyroptosis (involving inflammasome/caspase-1-mediated activation of pore-forming gasdermins),7 a mixture of pyroptosis, apoptosis, and necroptosis dubbed PANoptosis,8 ferroptosis (involving lethal membrane damage by peroxidation),9, 10 and cuproptosis (due to copper-induced aggregation of lipoylated dihydrolipoamide S-acetyltransferase).11 In all cases, cell death can be preceded by immunogenic stress that favors the emission of danger-associated molecular patterns (DAMPs) appearing on the surface of the cells or secreted into the extracellular space. It is the sum of stress-associated DAMPs (that are surface-exposed or released before cells disintegrate) and that of death-associated DAMPs (that become accessible or are passively released when the plasma membrane and internal membrane of cells become permeable) that dictates the immunogenicity of cell death and hence the capacity of the immune system to detect dead cell antigens. Such antigens can be microbial (for instance in the context of infection by viruses or intracellular bacteria), tumor-associated, or autoantigens. Immunogenic cell death is not only induced by drugs but can also occur in the context of radiation therapy,12 photodynamic, and photothermal therapy,13 as well upon infection by microbes including oncolytic viruses.14 Logically, attempts are underway to create novel galenic formulation including nanoparticle-based drug delivery systems to administer drugs that induce immunogenic cell death in tumors, yet do not mediate any systemic effects.13, 15 Interestingly, cell death of cancer cells can be accompanied by the release of nanoscale extracellular vesicles dubbed exosomes that constitute potential biomarkers of ongoing cell death events and establish short- and long-distance communication with neighboring cells and distant tissues.16 As a possibility, such exosomes might be engineered for the nanodelivery of therapeutic agents. When cells undergo immunogenic stress and death, they interact primarily with dendritic cells,17 in particular with Type-1 conventional dendritic cells (cDC1) that appear to be particularly competent in eliciting responses against dead cell antigens.18 Dendritic cells can be loaded with stressed and dying cancer cells and then be used as prophylactic or therapeutic vaccines.17 Moreover, dendritic cells can be manipulated pharmacologically to enhance their capacity to present tumor antigens to T cells.18 Such dendritic cells educate cytotoxic T lymphocytes to recognize and lyse malignant cells. Importantly, this process of T-cell-mediated cytotoxicity can elicit immunogenic cell death, hence amplifying the phenomenon and protracting the anticancer immune response.19 However, cell death affecting immune cells may play down such a desirable immunosurveillance. Specifically, it appears that dying neutrophil granulocytes produce so-called neutrophil extracellular traps (NETs) that shield cancer cells from cytotoxic immunity, hence impairing their clearance.20 Moreover, dying neutrophils can stimulate unwarranted inflammatory and autoimmune responses.21 Altogether, this volume of Immunological Reviews illustrates to which extent different cell stress and death modalities affecting malignant cells, pathogen-infected cells, or immune cells can elicit innate and cognate immune responses with vast consequences for whole-body physiology. It appears that processes that for long have been studied exclusively by cell biologists have acquired a major immunological dimension that already yields tangible impact with respect to the clinical management of malignant diseases. Future will tell whether the knowledge generated in this field will also contribute to the prevention and treatment of infectious and autoimmune diseases. The authors declare no relevant conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
愤怒的小曲奇应助wsqg123采纳,获得10
刚刚
不配.应助钱觅柔采纳,获得10
1秒前
2秒前
星辰大海应助念姬采纳,获得10
3秒前
8R60d8应助ZHAO采纳,获得10
3秒前
3秒前
李玟发布了新的文献求助10
4秒前
舒服的元瑶完成签到,获得积分10
4秒前
亓总关注了科研通微信公众号
5秒前
andrele发布了新的文献求助10
6秒前
7秒前
小六子123完成签到,获得积分10
7秒前
独特的兰发布了新的文献求助10
7秒前
fff完成签到,获得积分20
8秒前
9秒前
张秉环发布了新的文献求助10
10秒前
汉堡包应助Dusk大寺柯采纳,获得10
10秒前
11秒前
杳鸢应助钱觅柔采纳,获得10
13秒前
李健的小迷弟应助jam采纳,获得10
13秒前
乐乐应助乐观小蕊采纳,获得10
13秒前
15秒前
独特的兰完成签到,获得积分20
16秒前
范马勇次郎完成签到,获得积分10
16秒前
火星上的闭月完成签到 ,获得积分10
17秒前
17秒前
工仔完成签到,获得积分10
19秒前
冷傲凝琴发布了新的文献求助10
19秒前
cc应助大力浩轩采纳,获得10
19秒前
Owen应助大力浩轩采纳,获得10
19秒前
故意的青枫应助大力浩轩采纳,获得10
19秒前
善学以致用应助大力浩轩采纳,获得10
19秒前
roger应助大力浩轩采纳,获得10
19秒前
20秒前
ZZZZZZZ发布了新的文献求助10
21秒前
爆米花应助俭朴山兰采纳,获得10
22秒前
22秒前
24秒前
香蕉觅云应助penguin采纳,获得10
25秒前
26秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3222964
求助须知:如何正确求助?哪些是违规求助? 2871692
关于积分的说明 8176873
捐赠科研通 2538636
什么是DOI,文献DOI怎么找? 1370695
科研通“疑难数据库(出版商)”最低求助积分说明 645857
邀请新用户注册赠送积分活动 619776